GleamWall
中文EN

NYXH Nyxoah SA IFRS

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1857190 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY121.6%
TTM net income YoY-52.1%
TTM EPS YoY-30.7%
Revenue 3-yr CAGR48.1%
Net income 3-yr CAGR—

Margins

Gross margin63.1%
Operating margin-833.2%
Net margin-899.1%
FCF margin-696.4%
EBITDA margin—

Returns

ROE-111.0%
ROA-65.1%
ROIC (approx.)-134.3%
Asset turnover0.07x

Leverage & solvency

Liabilities / assets58.5%
Debt / equity0.00x
Current ratio1.25x
Interest coverage-7.25x

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-15.2%
Payout ratio—
Capex / revenue8.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: EUR FY20252025-12-31FY20242024-12-31
Income statement
Revenue10.02M4.52M
Cost of revenue3.69M1.55M
Gross profit6.33M2.97M
R&D expense42.82M34.33M
SG&A expense48.26M28.46M
Operating income-83.48M-58.81M
Interest expense11.52M5.07M
Pretax income-89.08M-56.43M
Income tax1.01M2.80M
Net income-90.08M-59.24M
EPS (basic)-2.36-1.81
EPS (diluted)-2.36-1.81
Balance sheet
Cash & equivalents30.00M34.19M
Receivables5.25M3.38M
Inventory4.66M4.72M
Current assets61.21M98.08M
PP&E, netmay include right-of-use assets (IFRS)4.05M4.75M
Intangibles50.11M50.38M
Total assets118.47M158.41M
Current liabilities48.96M21.53M
Total liabilities69.34M45.15M
Shareholders' equity49.13M113.25M
Shares outstanding43.03M37.43M
Cash flow statement
Operating cash flow-68.98M-49.23M
Capital expenditure805,0001.17M
Free cash flow-69.78M-50.39M
Investing cash flow28.33M-16.32M
Financing cash flow38.11M77.44M
Stock-based compensation4.89M3.97M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.